ArticleJournal of orthopaedic surgery and research2025
Reactive oxygen species-associated molecular landscape uncovers diagnostic and immune features in osteoarthritis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a prevalent degenerative joint disease characterized by joint inflammation and degradation. Reactive oxygen species (ROS) are implicated in the pathogenesis of OA, yet the molecular pathways linking ROS-related genes to the immune microenvironment remain poorly understood.
methodsWe integrated publicly available OA gene expression datasets and performed batch correction. ROS-related pathways were curated from the MSigDB, and pathway activity was assessed using ssGSEA. We identified differentially expressed genes (DEGs) in both training and validation cohorts, followed by GO and KEGG enrichment analyses. An elastic net regression model was constructed to calculate a risk score based on critical ROS-related DEGs. Model performance was evaluated using ROC, PR curves, calibration, and decision curve analysis. We also explored microRNA and transcription factor networks alongside genetic associations via the GWAS Catalog. Correlations among risk scores, inflammatory cytokines, and immune/stromal cell infiltration were systematically analyzed. An OA model was induced in rat fibroblast-like synoviocyte (FLS) cells via LPS treatment, and a corresponding rat OA model was established. The influence of ROS on FLS cell migration was validated through wound healing assays and Transwell assays. The expression of inflammatory markers and potential ROS-related biomarkers was evaluated using Western blotting and qRT-PCR. Additionally, the fluorescent probe DCFH-DA was used to detect the ROS levels.
resultsTranscriptomic analysis indicated significant dysregulation of ROS-related pathways in OA. Upregulated DEGs were associated with extracellular matrix and immune response processes, while downregulated genes were primarily linked to metabolic functions. The risk score comprising seven genes demonstrated high diagnostic accuracy. Network analyses revealed intricate regulatory mechanisms and genetic associations. The risk score positively correlated with inflammatory cytokines and immune cell infiltration, particularly fibroblasts. In vitro and in vivo experiments confirmed that LPS treatment significantly enhances FLS cell migration, upregulates OA-related inflammatory markers and ROS levels.
conclusionsThis study establishes a significant ROS-related gene signature with diagnostic and immunological relevance in OA, offering potential pathways for the development of novel biomarkers and targeted therapies focusing on ROS and immune responses in OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.